Autopsy report · NCT07656792

A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contraceptive in the Blood

“Sponsor decision - hold following the evaluation of a safety event. No current sites in the US.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 months before it stopped.
• 8 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Boehringer Ingelheim

Sponsor type

Industry

Conditions

Healthy

Interventions

BI 3031185; Placebo matching BI 3031185; Midazolam; YAZ®

Participants

8

Sites

1

Countries

Japan

Trials that died the same way

• Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
  “Sponsor decision (not due to safety concerns)” (78% match in meaning)
• A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts
  “Sponsor decision, not safety related” (78% match in meaning)
• NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
  “sponsor decision (not for safety)” (78% match in meaning)
• XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
  “Sponsor decision; Not a safety decision” (76% match in meaning)
• Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
  “Sponsor decision (not related to safety, efficacy or quality).” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.